This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Stocks to Watch Out For Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Western Digital (WDC), DocuSign (DOCU) & Kaiser Aluminum (KALU) are some of the stocks that at present are showing superb earnings acceleration, which may lead to an uptick in the stock price.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
TG Therapeutics (TGTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -32.69% and -20.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Earnings Preview: TG Therapeutics (TGTX) Q1 Earnings Expected to Decline
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in TG Therapeutics (TGTX): Can Its 6.7% Jump Turn into More Strength?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Company News for Mar 3, 2021
by Zacks Equity Research
Companies in The News Are: KSS,AZO,TGTX,KTB
TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -24.56% and -5.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
3 Soaring MedTech Stocks That Might Lose Ground in 2021
by Trina Mukherjee
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
Company News for Dec 11, 2020
by Zacks Equity Research
Companies in The News Are: CIEN,ASO,DIS,TGTX
TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -78.05% and -5.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and -5.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why TG Therapeutics (TGTX) is a Great Choice
by Zacks Equity Research
Does TG Therapeutics (TGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
TG Therapeutics (TGTX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Options Traders Expect Huge Moves in TG Therapeutics (TGTX) Stock
by Zacks Equity Research
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
TG Therapeutics (TGTX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
TG Therapeutics' Shares Soar on Positive Early-Stage Data
by Zacks Equity Research
TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.
Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.
Company News For Apr 2, 2019
by Zacks Equity Research
Companies in the news are: JNJ, SCOR, VFF and TGTX
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
by Zacks Equity Research
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.